Myst Therapeutics

Myst Therapeutics Focuses on Advancing Novel T-cell Therapies to Treat Solid Tumors, Aiming to Harness the Patient's Own Immune System to Destroy Cancer Cells. We Are Pursuing the Development of Adoptive Cell Therapy Utilizing Neoantigen-reactive T Cells Derived from Tumors and Peripheral Blood. Myst Plans to Combine Methods for Identifying Neoantigen-reactive T Cells from Tumor-infiltrating Lymphocytes (TILs) with Cutting-edge Technologies in Cell Sorting, T-cell Revitalization, and Industry-leading Expertise in Cell Therapy Development and Manufacturing. We Believe This Combination Will Enable Myst to Rapidly Advance and Commercialize These Highly Promising and Innovative Neoantigen-targeted Therapies for the Treatment of Solid Tumors.